105 related articles for article (PubMed ID: 1686602)
1. Plicamycin-hydroxyurea association in chronic granulocytic leukemia and multidrug resistance.
Papineschi F; Carulli G; Petrini M
Haematologica; 1991; 76(4):349. PubMed ID: 1686602
[No Abstract] [Full Text] [Related]
2. The plicamycin and hydroxyurea combination chemotherapy for chronic granulocytic leukemia in myeloid transformation.
Antimi M; Masi M; Delannoy A; Ferrant A; Doyen C; Debusscher L; Delwiche F; Stryckmans P; Papa G
Haematologica; 1990; 75(5):443-6. PubMed ID: 2151448
[TBL] [Abstract][Full Text] [Related]
3. [P-glycoprotein and treatment with plicamycin + hydroxyurea in myeloid blastic crisis of chronic myeloid leukemia].
Carulli G; Marini A; Caracciolo F
Medicina (Firenze); 1989; 9(4):409-10. PubMed ID: 2576761
[TBL] [Abstract][Full Text] [Related]
4. Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.
Trümper LH; Ho AD; Hunstein W; van der Lelie H; Goudsmit R
Blut; 1989 Feb; 58(2):85-7. PubMed ID: 2522015
[TBL] [Abstract][Full Text] [Related]
5. [Myeloid crisis of chronic myelogenous leukemia showing dramatic response to mithramycin and hydroxyurea combination].
Ueki K; Tsuchida A; Murakami H; Karasawa M; Kobayashi N; Omine M; Naruse T
Rinsho Ketsueki; 1989 Oct; 30(10):1840-2. PubMed ID: 2531808
[TBL] [Abstract][Full Text] [Related]
6. Therapy of the blast phase of chronic granulocytic leukemia with mithramycin and hydroxyurea.
Queisser W; Herrmann F; Lindemann A; Anger B; Hiddemann W; Krey U
Onkologie; 1988 Jun; 11(3):145-6. PubMed ID: 2970612
[No Abstract] [Full Text] [Related]
7. [Chronic myelogenous leukemia with blastic crisis in which expression of P-glycoprotein was associated with resistance to chemotherapy].
Utsunomiya A; Kuwazuru Y; Chuman Y; Mishige Y; Saito T; Terada A; Iwahashi M; Hanada S; Yoshimura A; Akiyama S
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1915-8. PubMed ID: 1355642
[TBL] [Abstract][Full Text] [Related]
8. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea.
Koller CA; Miller DM
N Engl J Med; 1986 Dec; 315(23):1433-8. PubMed ID: 2431313
[TBL] [Abstract][Full Text] [Related]
9. Failure of mithramycin to control the myeloid blast phase of chronic granulocytic leukemia: a report on nine patients and review of the literature.
Johnson PR; Yin JA; Narayanan MN; Geary CG; Love EM; Cinkotai KI
Hematol Oncol; 1991; 9(1):9-15. PubMed ID: 1828453
[TBL] [Abstract][Full Text] [Related]
10. Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis.
Kuwazuru Y; Yoshimura A; Hanada S; Ichikawa M; Saito T; Uozumi K; Utsunomiya A; Arima T; Akiyama S
Br J Haematol; 1990 Jan; 74(1):24-9. PubMed ID: 1968762
[TBL] [Abstract][Full Text] [Related]
11. Tetrasomy of Philadelphia chromosome in myeloblastic crisis of chronic myelogenous leukemia.
Oikawa H; Utsugisawa T; Murai K; Narigasawa Y; Miyairi Y; Shimosegawa K; Suzuki T; Kuriya S
Int J Hematol; 1995 Jun; 61(4):229-30. PubMed ID: 8547613
[No Abstract] [Full Text] [Related]
12. Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia.
Pirker R; Goldstein LJ; Ludwig H; Linkesch W; Lechner C; Gottesman MM; Pastan I
Cancer Commun; 1989; 1(2):141-4. PubMed ID: 2639725
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic granulocytic leukemia in blastic crisis.
Canellos GP
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():131-2. PubMed ID: 2565744
[No Abstract] [Full Text] [Related]
15. Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge.
Nand S; Barton K
Leuk Lymphoma; 2007 Feb; 48(2):215-6. PubMed ID: 17325875
[No Abstract] [Full Text] [Related]
16. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyurea.
Jehn U; Heinemann V
Cancer Detect Prev; 1998; 22(3):258-64. PubMed ID: 9618049
[TBL] [Abstract][Full Text] [Related]
17. Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Stagno F; Stella S; Berretta S; Massimino M; Antolino A; Giustolisi R; Messina A; Di Raimondo F; Vigneri P
Leuk Res; 2008 Apr; 32(4):673-4. PubMed ID: 17889935
[No Abstract] [Full Text] [Related]
18. The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
Weide R; Dowding C; Paulsen W; Goldman J
Leukemia; 1990 Oct; 4(10):695-9. PubMed ID: 1976871
[TBL] [Abstract][Full Text] [Related]
19. Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?
Mahadevan D
Leuk Res; 2006 Sep; 30(9):1077-8. PubMed ID: 16678260
[No Abstract] [Full Text] [Related]
20. Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
Breccia M; Serrao A; Salaroli A; Loglisci G; Zacheo I; Alimena G
Br J Haematol; 2012 Dec; 159(5):612-3. PubMed ID: 23043319
[No Abstract] [Full Text] [Related]
[Next] [New Search]
